Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Influenza vaccines

a technology of influenza vaccine and antigen, applied in the field of medicine, can solve the problems of not being suited to controlling pandemics, constant antigenic changes in ha, emergence of variant or new virus strains, etc., and achieve the effects of increasing the cross-reactive immune response, reducing the potency of influenza ha-containing antigen, and reducing the risk of infection

Inactive Publication Date: 2015-04-09
KJ BIOSCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides an influenza vaccine that can provide increased cross-reactive immune response and cross protection against variant or heterologous viruses. The vaccine contains an influenza HA-containing antigen that is treated at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency. The resulting vaccine can induce the increased cross-reactive antibody responses and cross protection that is associated with the increased cross reaction with HA2, the highly conserved part of HA. The vaccine can provide the same level of strain-specific immune responses and protection against viruses contained in the vaccine as with untreated antigen or like current inactivated vaccines, and at the same time also an increased cross-reactive immune response and cross protection against viruses not contained in the vaccine, including the possible pandemic as well as seasonal variant viruses. The new influenza vaccine can be made with single or multiple antigens and is highly suited for production of a new TIV based on the same three antigens (H1, H3, and B) or a quadrivalent inactivated vaccine that incorporates treated antigens from all three or at least H1 and H3 strains. The method for manufacturing the vaccine involves treating an influenza antigen with low pH and temperature to obtain a suitable degree of loss of potency, formulating it with pharmaceutically acceptable carriers, and compensating the partial potency loss with additional antigens or an adjuvant. The resulting vaccine will induce the strain-specific immune responses and protection like current inactivated vaccines.

Problems solved by technology

Influenza viruses undergo constant genetic changes due to its error prone replication and ability to reassort genome segments, resulting in constant antigenic changes in HA and emergence of variant or new virus strains.
The constant antigenic changes of influenza viruses pose a great challenge to developing vaccines for controlling influenza epidemics and pandemics.
Current TIVs (H1, H3, and B) are strain-specific and are not suited for controlling pandemics.
The cross-reactive antibodies against highly conserved domains can be produced by vaccination with current vaccines or after infection, but only at low levels not sufficient to provide protection.
The non-neutralizing antibodies may not prevent infection, but can reduce the incidence and severity of the disease.
However, it is a formidable task and may take a long development process before it can be approved for use in people (Nabel and Fauci, Nat Med. 16:1389-91, 2010; Rappuoli, F1000 Med Rep. 3:16, 2011).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza vaccines
  • Influenza vaccines
  • Influenza vaccines

Examples

Experimental program
Comparison scheme
Effect test

example 1

Potency of Inactivated Influenza Whole Virus (WV) Antigens Following Low pH Treatment

[0066]Inactivated WV antigens from three virus strains (A / New Caledonia / 20 / 99, H1 H1 (H1N1 NC); A / Wisconsin / 67 / 2005, H3N2 (H3N2 Wis); B / Malaysia / 2506 / 2004 (B Mal) were used. They were produced by purification from infected MDCK cells and inactivation with formaldehyde (1 / 4000 dilution or 0.01%) for at least three days at 4° C. The inactivation was confirmed by titration in chicken eggs and plaque assay in MDCK cells.

[0067]For low pH treatment, antigens in phosphate buffered saline (PBS, pH 7.2; ˜2.0 mg / ml) were diluted 1:10 with 20 mM sodium citrate buffers containing 150 mM NaCl (pH 4.6-5.4 in 0.2 increments) to bring the pH of antigens to 4.9-5.5 with a final antigen concentration at ˜0.2 mg / ml. The antigens were then kept at 0° C. (on ice), 4° C., 25° C. (room temperature), or 37° C. for 15 min before the pH was adjusted with an appropriate volume of 1 M Tris HCl buffer (pH 8.0) back to the origi...

example 2

Potency of Trivalent Inactivated Vaccine (TIV) Following Low pH Treatment

[0071]A TIV (Fluzone, 2006-2007) which contains the antigens from the same three virus strains described in Example 1 was also evaluated for potency after low pH treatment under different conditions. The vaccine was similarly treated, but with appropriate volumes of 0.1 M HCl added to the vaccine to adjust the pH to a similar range before neutralization with an equal volume of 0.1 M NaOH. The potency of H1N1 NC strain was measured. The results were similar to those obtained with inactivated WV antigens as described above (FIG. 1B and Table 3). However, TIV was more susceptible to low pH treatment than the WV antigen in that at any given condition, potency loss was greater with TIV. This may be related to the fact that TIV is made of split antigens. A complete potency loss (100%) was obtained at 37° C. for all pH levels tested (FIG. 1B and Table 3). Similarly, hemagglutination activity only decreased by 2 fold o...

example 3

Induction of Increased Cross-Reactive Antibody Responses by Low pH-Treated Antigens

[0073]Low pH-treated H1N1 NC WV antigens with different levels of potency loss were used to immunize 6-8 weeks old female Balb / c mice (n=7) together with the untreated control. The antigens were treated at pH 5.1 and different temperatures (0, 25, and 37° C.) and the potency (HA, μg / ml) was determined as described in Example 1. The treated antigens exhibited the potency reduction in correlation with the treatment conditions, but retained the original hemagglutination activity (Table 5).

[0074]Mice were immunized at the same antigen dose based on total proteins which was equivalent to 1 μg HA / mouse for untreated antigen by intramuscular injection twice, 4 weeks apart. A group receiving a mixture of antigens containing equal parts of the untreated antigen and the one treated at 37° C. was also included (Table 5). The mixed antigen exhibited a similar level of potency as the untreated antigen as expected ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.

Description

GOVERNMENT SUPPORT[0001]This invention was made with government support under Grant No. A1092923 awarded by the National Institutes of Health. The U.S. Government has certain rights in the invention.FIELD OF THE INVENTION[0002]The present invention relates generally to the field of medicine, and specifically to microbiology, immunology, and vaccines, and more specifically, influenza vaccines.BACKGROUND OF THE INVENTION[0003]There are three types of influenza viruses, A, B, and C. Influenza A and B viruses are responsible for most of infections and related diseases in humans and animals. Influenza A virus has been associated with all influenza pandemics with the latest one in 2009. Influenza viruses have two major glycoproteins anchored on its membrane envelope, hemagglutinin (HA) and neuraminidase (NA). The HA is responsible for mediating virus entry into target cells through binding to cell receptors and mediating fusion between viral and cell membranes. The HA is also the major ta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/145C12N7/00
CPCA61K39/145C12N7/00C12N2760/16134C12N2760/16161C12N2760/16151A61K2039/5252A61K2039/525A61K39/12A61K2039/58A61K2039/70C12N2760/16234
Inventor NI, YAWEIGUO, JIANHUA
Owner KJ BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com